Search
01/07/2022
Re: Percutaneous Nephrolithotomy in Horseshoe Kidneys: Results of a Multicentric Study
Vicentini, FC, Mazzucchi, E, Gokce, MI, Sofer, M, Tanidir, Y, Sener, TE, Melo, PAD, Eisner, B, Batter, TH, Chi, T, Armas-Phan, M, Scoffone, CM, Cracco, CM, Perez, BOM, Angerri, O, Emiliani, E, Maugeri, O, Stern, K, Batagello, CA, Monga, M. Re: Percutaneous Nephrolithotomy in Horseshoe Kidneys: Results of a Multicentric Study. JOURNAL OF UROLOGY. 2022; 208(1)DOI:. PMID:. IF:6.600(Q1/2D).
01/07/2022
Benefit and Harm of Active Surveillance for Biopsy-proven Renal Oncocytoma: A Systematic Review and Pooled Analysis
Baboudjian, M, Moser, D, Yanagisawa, T, Gondran-Tellier, B, Comperat, EM, Ambrosetti, D, Daniel, L, Bastide, C, Shariat, SF, Lechevallier, E, Diana, P, Breda, A, Pradere, B, Boissier, R. Benefit and Harm of Active Surveillance for Biopsy-proven Renal Oncocytoma: A Systematic Review and Pooled Analysis. European Urology Open Science. 2022; 41DOI:10.1016/j.euros.2022.04.009. PMID:35633831. IF:2.500(Q3/6D).
01/07/2022
Intracorporeal Versus Extracorporeal Robot-assisted Kidney Autotransplantation: Experience of the ERUS RAKT Working Group (vol 81, pg 168, 2022)
Breda, A, Diana, P, Territo, A, Gallioli, A, Piana, A, Gaya, JM, Gavrilov, P, Desender, L, Van Parys, B, Van Praet, C, Lambert, E, Khene, ZE, Dang, VT, Doumerc, N, Decaestecker, K. Intracorporeal Versus Extracorporeal Robot-assisted Kidney Autotransplantation: Experience of the ERUS RAKT Working Group (vol 81, pg 168, 2022). EUROPEAN UROLOGY. 2022; 82(1)DOI:10.1016/j.eururo.2022.03.026. PMID:35465984. IF:23.400(Q1/1D).
01/07/2022
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guerin-exposed High-risk Non-muscle-invasive Bladder Cancer
Roumiguie, M, Kamat, AM, Bivalacqua, TJ, Lerner, SP, Kassouf, W, Bohle, A, Brausi, M, Buckley, R, Persad, R, Colombel, M, Lamm, D, Palou-Redorta, J, Soloway, M, Brothers, K, Steinberg, G, Lotan, Y, Sylvester, R, Witjes, JA, Black, PC. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guerin-exposed High-risk Non-muscle-invasive Bladder Cancer. EUROPEAN UROLOGY. 2022; 82(1)DOI:10.1016/j.eururo.2021.12.005. PMID:34955291. IF:23.400(Q1/1D).